As you are aware the EU Clinical Trials Directive is set to become part of the UK’s regulatory and legal landscape from 1 May, 2004. Richmond Pharmacology has welcomed the directive which will help to harmonise trial standards across the board.We support the MHRA (Medicines and Healthcare products Regulatory Agency) which regulates implementation of the Directive, and we applaud our industry partners who have ensured that the implementation does not slow down or hinder the competitiveness of the UK’s clinical research industry.We have put together a guide on the EU Directive following numerous client requests for more information and greater clarity on how the directive will impact on research projects, timelines and approval systemsTo request a copy of the guide please email a.hurd@richmondpharmacology.com

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event